Compare AstraZeneca plc (AZN) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Impinj Inc — how do they compare? AstraZeneca plc trades at $166.73 (market cap $253.13B), while Impinj Inc trades at $147.48 (market cap $4.40B). The key difference: AstraZeneca plc is far larger — about 57.5× Impinj Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Impinj Inc pays none. Which is the better fit depends on your goals.
| AZN | PI | |
|---|---|---|
Market Cap | $253.13B | $4.40B |
Sector | Health | Technology |
52-Week High | $209.48 | $241.91 |
52-Week Low | $137.44 | $91.34 |
Enterprise Value | $279.37B | $4.54B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Impinj (PI) trades at $146.02, up 1.38% with a bullish technical signal supported by moving averages. The company shows mixed fundamentals with a negative net income margin of -7.66% but beat Q1 2026 EPS estimates. Revenue remains stable at $361M annually, though profitability challenges persist with elevated valuation ratios like P/S of 11.89. Analyst consensus is strongly bullish with 73% buy ratings and a $167.50 price target.
Outlook remains cautiously optimistic given strong analyst support and technical momentum, but investors face risks from insider selling and ongoing profitability challenges. The stock offers potential upside to consensus targets if execution improves, though negative margins and competitive pressures warrant careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
